Search

Your search keyword '"Badawy, Sherif M."' showing total 365 results
Start Over Author "Badawy, Sherif M." Publication Year Range Last 3 years
365 results on '"Badawy, Sherif M."'

2. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease

Author

Hankins, Jane S, Brambilla, Donald, Potter, Michael B, Kutlar, Abdullah, Gibson, Robert, King, Allison A, Baumann, Ana A, Melvin, Cathy, Gordeuk, Victor R, Hsu, Lewis L, Nwosu, Chinonyelum, Porter, Jerlym S, Alberts, Nicole M, Badawy, Sherif M, Simon, Jena, Glassberg, Jeffrey A, Lottenberg, Richard, DiMartino, Lisa, Jacobs, Sara, Fernandez, Maria E, Bosworth, Hayden B, Klesges, Lisa M, Shah, Nirmish, Hodges, Jason, Carroll, Yvonne, Klesges, Lisa, Khan, Hamda, Smeltzer, Matthew, Gurney, James, Porter, Jerlym, Alberts, Nicole, French, Reginald, Badawy, Sherif, DeBaun, Michael, Kang, Guolian, Estepp, Jeremie, Wang, Winfred, Owens, Curtis, Debon, Margaret, Osarogiagbon, Ray, Nelson, Marquita, Treadwell, Marsha, Vichinsky, Elliott, Wun, Ted, Potter, Michael, Hessler, Danielle, Hagar, Ward, Marsh, Anne, Neumayr, Lynne, Kanter, Julie, Phillips, Shannon, Adams, Robert, Mueller, Martina, Abrams, Tina, Davia, Nathalia, Tanabe, Paula, Bosworth, Hayden, Jackson, George, Johnson, Fred, Richesson, Rachel, Prvu-Bettger, Janet, King, Allison, Baumann, Ana, Calhoun, Cecilia, Snyder, Angie, Fernandez, Maria, Richardson, Lynne D, Glassberg, Jeffrey, Genes, Nicholas G, Loo, George T, Shapiro, Jason S, Souffront, Kimberly, Clesca, Cindy, Linton, Elizabeth, Ryan, Gery, Kroner, Barbara L, Hendershot, Tabitha, Battestilli, Whitney, Cox, Lisa, Preiss, Liliana, Pugh, Norma, Li, Sophie, VonLehmden, Annie, Smith, Sharon M, Tonkins, William P, Peters-Lawrence, Marlene, Boyce, Cheryl, Barfield, Whitney, and Thompson, Alexis

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Services, Clinical Trials and Supportive Activities, Chronic Pain, Pain Research, Hematology, Sickle Cell Disease, Clinical Research, Rare Diseases, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Female, Humans, Male, Anemia, Sickle Cell, Hydroxyurea, Medication Adherence, Pain, Telemedicine, Cardiovascular medicine and haematology
Abstract

Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center, non-randomized trial of individuals with SCD ages 15-45. We compared the percentage of days covered (PDC), labs, healthcare utilization, and self-reported pain over 24 weeks of intervention and 12 weeks post-study with a 24-week preintervention interval. We enrolled 293 patients (51% male; median age 27.5 years, 86.8% HbSS/HbSβ0-thalassemia). The mean change in PDC among 235 evaluable subjects increased (39.7% to 56.0%; P < 0.001) and sustained (39.7% to 51.4%, P < 0.001). Mean HbF increased (10.95% to 12.78%; P = 0.03). Self-reported pain frequency reduced (3.54 to 3.35 events/year; P = 0.041). InCharge Health was used ≥1 day by 199 of 235 participants (84.7% implementation; median usage: 17% study days; IQR: 4.8-45.8%). For individuals with ≥1 baseline admission for pain, admissions per 24 weeks declined from baseline through 24 weeks (1.97 to 1.48 events/patient, P = 0.0045) and weeks 25-36 (1.25 events/patient, P = 0.0015). PDC increased with app use (P < 0.001), with the greatest effect in those with private insurance (P = 0.0078), older subjects (P = 0.033), and those with lower pain interference (P = 0.0012). Of the 89 providers (49 hematologists, 36 advanced care providers, 4 unreported), only 11.2% used HU Toolbox ≥1/month on average. This use did not affect change in PDC. Tailoring mHealth solutions to address barriers to hydroxyurea adherence can potentially improve adherence and provide clinical benefits. A definitive randomized study is warranted. This trial was registered at www.clinicaltrials.gov as #NCT04080167.

Published
2023

4. An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model

Author

Treadwell, Marsha J, Mushiana, Swapandeep, Badawy, Sherif M, Preiss, Liliana, King, Allison A, Kroner, Barbara, Chen, Yumei, Glassberg, Jeffrey, Gordeuk, Victor, Shah, Nirmish, Snyder, Angela, and Wun, Theodore

Subjects
Health Sciences, Mind and Body, Mental Health, Rare Diseases, Hematology, Sickle Cell Disease, Clinical Research, Behavioral and Social Science, Chronic Pain, Pain Research, Neurosciences, Adolescent, Adult, Anemia, Sickle Cell, Humans, Middle Aged, Pain, Patient Reported Outcome Measures, Quality of Life, Surveys and Questionnaires, Young Adult, Patient-reported outcome measures, Sickle cell disease, Implementation science, Models-biopsychosocial, Sickle Cell Disease Implementation Consortium, Models—biopsychosocial, Public Health and Health Services, Psychology, Health Policy & Services, Health sciences, Human society
Abstract

PurposeTo examine the relations between patient-reported outcomes (PROs) within a conceptual model for adults with sickle cell disease (SCD) ages 18 - 45 years enrolled in the multi-site Sickle Cell Disease Implementation Consortium (SCDIC) registry. We hypothesized that patient and SCD-related factors, particularly pain, and barriers to care would independently contribute to functioning as measured using PRO domains.MethodsParticipants (N = 2054) completed a 48-item survey including socio-demographics and PRO measures, e.g., social functioning, pain impact, emotional distress, and cognitive functioning. Participants reported on lifetime SCD complications, pain episode frequency and severity, and barriers to healthcare.ResultsHigher pain frequency was associated with higher odds of worse outcomes in all PRO domains, controlling for age, gender and site (OR range 1.02-1.10, 95% CI range [1.004-1.12]). Reported history of treatment for depression was associated with 5 of 7 PRO measures (OR range 1.58-3.28 95% CI range [1.18-4.32]). Fewer individual barriers to care and fewer SCD complications were associated with better outcomes in the emotion domain (OR range 0.46-0.64, 95% CI range [0.34-0.86]).ConclusionsStudy results highlight the importance of the biopsychosocial model to enhance understanding of the needs of this complex population, and to design multi-dimensional approaches for providing more effective interventions to improve outcomes.

Published
2022

6. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study

Author

Kahn, Justine, Brazauskas, Ruta, Bo-Subait, Stephanie, Buchbinder, David, Hamilton, Betty K, Schoemans, Hélène, Abraham, Allistair A, Agrawal, Vaibhav, Auletta, Jeffery J, Badawy, Sherif M, Beitinjaneh, Amer, Bhatt, Neel S, Broglie, Larisa, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, Cesar O, Gale, Robert Peter, Ganguly, Siddhartha, Hayashi, Robert J, Hematti, Peiman, Hildebrandt, Gerhard C, Inamoto, Yoshihiro, Kamble, Rammurti T, Koo, Jane, Lazarus, Hillard M, Mayo, Samantha J, Mehta, Parinda A, Myers, Kasiani C, Nishihori, Taiga, Prestidge, Tim, Rotz, Seth J, Savani, Bipin N, Schears, Raquel M, Sharma, Akshay, Stenger, Elizabeth, Ustun, Celalettin, Williams, Kirsten M, Vrooman, Lynda M, Satwani, Prakash, and Phelan, Rachel

Published
2024
Full Text
View/download PDF

8. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

10. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities

Author

Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad Bilal, Diaz Perez, Miguel Angel, Al-Homsi, A. Samer, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel M., Lazarus, Hillard M., Ciurea, Stefan, Badawy, Sherif M., Savani, Bipin N., Wirk, Baldeep, LeMaistre, C. Fred, Bhatt, Neel S., Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer M., Kelkar, Amar H., Yared, Jean A., Kindwall-Keller, Tamila, Winestone, Lena E., Steinberg, Amir, Arnold, Staci D., Seo, Sachiko, Preussler, Jaime M., Hossain, Nasheed M., Fingrut, Warren B., Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie E., Wood, William A., Rangarajan, Hemalatha G., Saber, Wael, and Hahn, Theresa

Published
2024
Full Text
View/download PDF

11. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

12. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients

Author

Zinter, Matt S., Brazauskas, Ruta, Strom, Joelle, Chen, Stella, Bo-Subait, Stephanie, Sharma, Akshay, Beitinjaneh, Amer, Dimitrova, Dimana, Guilcher, Greg, Preussler, Jaime, Myers, Kasiani, Bhatt, Neel S., Ringden, Olle, Hematti, Peiman, Hayashi, Robert J., Patel, Sagar, De Oliveira, Satiro Nakamura, Rotz, Seth, Badawy, Sherif M., Nishihori, Taiga, Buchbinder, David, Hamilton, Betty, Savani, Bipin, Schoemans, Hélène, Sorror, Mohamed, Winestone, Lena, Duncan, Christine, Phelan, Rachel, and Dvorak, Christopher C.

Published
2024
Full Text
View/download PDF

13. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

14. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author

Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.

Published
2022

15. Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA

Author

Smeltzer, Matthew P, Howell, Kristen E, Treadwell, Marsha, Preiss, Liliana, King, Allison A, Glassberg, Jeffrey A, Tanabe, Paula, Badawy, Sherif M, DiMartino, Lisa, Gibson, Robert, Kanter, Julie, Klesges, Lisa M, and Hankins, Jane S

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Clinical Sciences, Health Sciences, Sickle Cell Disease, Hematology, Pain Research, Rare Diseases, Clinical Research, Health Services, Chronic Pain, 8.1 Organisation and delivery of services, Health and social care services research, Good Health and Well Being, Anemia, Sickle Cell, Child, Cross-Sectional Studies, Evidence-Based Medicine, Health Personnel, Humans, Hydroxyurea, United States, mental health, haematology, paediatrics, Sickle Cell Disease Implementation Consortium, Public Health and Health Services, Other Medical and Health Sciences, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

ObjectivesSickle cell disease (SCD) leads to chronic and acute complications that require specialised care to manage symptoms and optimise clinical results. The National Heart Lung and Blood Institute (NHLBI) evidence-based guidelines assist providers in caring for individuals with SCD, but adoption of these guidelines by providers has not been optimal. The objective of this study was to identify barriers to treating individuals with SCD.MethodsThe SCD Implementation Consortium aimed to investigate the perception and level of comfort of providers regarding evidence-based care by surveying providers in the regions of six clinical centres across the USA, focusing on non-emergency care from the providers' perspective.ResultsRespondents included 105 providers delivering clinical care for individuals with SCD. Areas of practice were most frequently paediatrics (24%) or haematology/SCD specialist (24%). The majority (77%) reported that they were comfortable managing acute pain episodes while 63% expressed comfort with managing chronic pain. Haematologists and SCD specialists showed higher comfort levels prescribing opioids (100% vs 67%, p=0.004) and managing care with hydroxyurea (90% vs 51%, p=0.005) compared with non-haematology providers. Approximately 33% of providers were unaware of the 2014 NHLBI guidelines. Nearly 63% of providers felt patients' medical needs were addressed while only 22% felt their mental health needs were met.ConclusionsA substantial number of providers did not know about NHLBI's SCD care guidelines. Barriers to providing care for patients with SCD were influenced by providers' specialty, training and practice setting. Increasing provider knowledge could improve hydroxyurea utilisation, pain management and mental health support.

Published
2021

17. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author

Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.

Published
2023
Full Text
View/download PDF

18. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis

Author

Taylor, Mallory R., Cole, Steve W., Strom, Joelle, Brazauskas, Ruta, Baker, K. Scott, Phelan, Rachel, Buchbinder, David, Hamilton, Betty, Schoemans, Hélène, Shaw, Bronwen E., Sharma, Akshay, Bhatt, Neel S., Badawy, Sherif M., Winestone, Lena E., Preussler, Jaime M., Mayo, Samantha, Jamani, Kareem, Nishihori, Taiga, Lee, Michelle A., and Knight, Jennifer M.

Published
2023
Full Text
View/download PDF

20. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

21. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Author

Ballen, Karen, Wang, Tao, He, Naya, Knight, Jennifer M., Hong, Sanghee, Frangoul, Haydar, Verdonck, Leo F., Steinberg, Amir, Diaz, Miguel A., LeMaistre, C. Fred, Badawy, Sherif M., Pu, Jeffrey J., Hashem, Hasan, Savani, Bipin, Sharma, Akshay, Lazarus, Hillard M., Abid, Muhammad Bilal, Tay, Jason, Rangarajan, Hemalatha G., Kindwall-Keller, Tamila, Freytes, Cesar O., Beitinjaneh, Amer, Winestone, Lena E., Gergis, Usama, Farhadfar, Nosha, Bhatt, Neel S., Schears, Raquel M., Gómez-Almaguer, David, Aljurf, Mahmoud, Agrawal, Vaibhav, Kuwatsuka, Yachiyo, Seo, Sachiko, Marks, David I., Lehmann, Leslie, Wood, William A., Hashmi, Shahrukh, and Saber, Wael

Published
2024
Full Text
View/download PDF

22. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation

Author

Phelan, Rachel, Im, Annie, Hunter, Rebecca L., Inamoto, Yoshihiro, Lupo-Stanghellini, Maria Teresa, Rovo, Alicia, Badawy, Sherif M., Burns, Linda, Eissa, Hesham, Murthy, Hemant S., Prasad, Pinki, Sharma, Akshay, Suelzer, Elizabeth, Agrawal, Vaibhav, Aljurf, Mahmoud, Baker, Karen, Basak, Grzegorz W., Buchbinder, David, DeFilipp, Zachariah, Grkovic, Lana Desnica, Dias, Ajoy, Einsele, Hermann, Eisenberg, Michael L., Epperla, Narendranath, Farhadfar, Nosha, Flatau, Arthur, Gale, Robert Peter, Greinix, Hildegard, Hamilton, Betty K., Hashmi, Shahrukh, Hematti, Peiman, Jamani, Kareem, Maharaj, Dipnarine, Murray, John, Naik, Seema, Nathan, Sunita, Pavletic, Steven, Peric, Zinaida, Pulanic, Drazen, Ross, Richard, Salonia, Andrea, Sanchez-Ortega, Isabel, Savani, Bipin N., Schechter, Tal, Shah, Ami J., Smith, Stephanie M., Snowden, John A., Steinberg, Amir, Tremblay, Douglas, Vij, Sarah C., Walker, Lauren, Wolff, Daniel, Yared, Jean A., Schoemans, Hélène, and Tichelli, André

Published
2022
Full Text
View/download PDF

25. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML

Author

Menghrajani, Kamal, Gomez-Arteaga, Alexandra, Madero-Marroquin, Rafael, Zhang, Mei-Jie, Bo-Subait, Khalid, Sanchez, Jonathan, Wang, Hai-Lin, Aljurf, Mahmoud, Assal, Amer, Bacher, Vera Ulrike, Badawy, Sherif M., Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Christopher, Byrne, Michael, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Ciurea, Stefan Octavian, DeFilipp, Zachariah, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard, Kanakry, Christopher G., Kansagra, Ankit, Khimani, Farhad, Krem, Maxwell, Lazarus, Hillard, Liu, Hongtao, Martino, Rodrigo, Michelis, Fotios V., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Reshef, Ran, Rizzieri, David, Rowe, Jacob M., Savani, Bipin N., Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Weisdorf, Daniel, Zhang, Yanming, Tallman, Martin S., and Saber, Wael

Published
2022
Full Text
View/download PDF

27. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author

Bhatt, Vijaya Raj, Wang, Tao, Chen, Karen, Kitko, Carrie L., MacMillan, Margaret L., Pidala, Joseph A., Al Malki, Monzr M., Badawy, Sherif M., Beitinjaneh, Amer, Ganguly, Siddhartha, Hamilton, Betty, Hildebrandt, Gerhard C., Lekakis, Lazaros J., Liu, Hongtao, Maziarz, Richard T., Modi, Dipenkumar, Murthy, Hemant S., Preussler, Jaime M., Sharma, Akshay, Spellman, Stephen R., Arora, Mukta, and Lee, Stephanie J.

Published
2022
Full Text
View/download PDF

28. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

30. Mediators and Moderators of Cognitive-Behavioral Digital Health Intervention for Youth with Sickle Cell Disease Pain

Author

Srinakarin, Kavin, primary, Sanpoori, Shwetha, additional, Lalloo, Chitra, additional, Zhou, Chuan, additional, Dampier, Carlton, additional, Zempsky, William, additional, Badawy, Sherif M., additional, Bakshi, Nitya, additional, Ko, Yeon Joo, additional, Nishat, Fareha, additional, Stinson, Jennifer N., additional, and Palermo, Tonya M., additional

Published
2024
Full Text
View/download PDF

31. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Author

Bos, Saskia, primary, Murray, John, additional, Marchetti, Monia, additional, Cheng, Guang-Shing, additional, Bergeron, Anne, additional, Wolff, Daniel, additional, Sander, Clare, additional, Sharma, Akshay, additional, Badawy, Sherif M., additional, Peric, Zinaida, additional, Piekarska, Agnieszka, additional, Pidala, Joseph, additional, Raj, Kavita, additional, Penack, Olaf, additional, Kulkarni, Samar, additional, Beestrum, Molly, additional, Linke, Andrea, additional, Rutter, Matthew, additional, Coleman, Courtney, additional, Tonia, Thomy, additional, Schoemans, Hélène, additional, Stolz, Daiana, additional, and Vos, Robin, additional

Published
2024
Full Text
View/download PDF

34. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Arora, Mukta, Brazauskas, Ruta, Spellman, Stephen R., Kitko, Carrie, MacMillan, Margaret L., Pidala, Joseph A., Badawy, Sherif M., Bhatt, Neel, Bhatt, Vijaya R., DeFilipp, Zachariah, Diaz, Miguel A., Farhadfar, Nosha, Gadalla, Shahinaz, Hashmi, Shahrukh, Hematti, Peiman, Hossain, Nasheed M., Inamoto, Yoshihiro, Lekakis, Lazaros J., Sharma, Akshay, Solomon, Scott, Lee, Stephanie J., and Couriel, Daniel R.

Published
2024
Full Text
View/download PDF

35. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

Author

Blue, Brandon J., Brazauskas, Ruta, Chen, Karen, Patel, Jinalben, Zeidan, Amer M., Steinberg, Amir, Ballen, Karen, Kwok, Janette, Rotz, Seth J., Perez, Miguel Angel Diaz, Kelkar, Amar H., Ganguly, Siddhartha, Wingard, John R., Lad, Deepesh, Sharma, Akshay, Badawy, Sherif M., Lazarus, Hillard M., Hashem, Hasan, Szwajcer, David, Knight, Jennifer M., Bhatt, Neel S., Page, Kristin, Beattie, Sara, Arai, Yasuyuki, Liu, Hongtao, Arnold, Staci D., Freytes, César O., Abid, Muhammad Bilal, Beitinjaneh, Amer, Farhadfar, Nosha, Wirk, Baldeep, Winestone, Lena E., Agrawal, Vaibhav, Preussler, Jaime M., Seo, Sachiko, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William A., Rangarajan, Hemalatha G., Saber, Wael, and Majhail, Navneet S.

Published
2023
Full Text
View/download PDF

36. What is in a name: defining pediatric refractory ITP

Author

Nakano, Taizo A., Grimes, Amanda B., Klaassen, Robert J., Lambert, Michele P., Neunert, Cindy, Rothman, Jennifer A., Shimano, Kristin A., Amend, Christina, Askew, Megan, Badawy, Sherif M., Baker, Jillian M., Breakey, Vicky, Crary, Shelley, Davini, Monica, Fritch Lilla, Stephanie, Gilbert, Megan, Hays, Taru, Hege, Kerry, Hillier, Kirsty, Jacobson-Kelly, Amanda, Kaicker, Shipra, Kim, Taylor O., Kochhar, Manpreet, Leblanc, Thierry, Martinelli, Marie, Nunez, Mara, Remiker, Allison, Schultz, Corrina, Sharma, Ruchika, and Grace, Rachael F.

Abstract

There are no agreed upon terminology to define “refractory” pediatric immune thrombocytopenia (ITP). Guidelines are therefore limited to arbitrary and outdated definitions. The Pediatric ITP Consortium of North America held a meeting in 2023 to define this entity. With 100% agreement, the faculty established that pediatric ITP that is refractory to emergent therapy could be defined as no platelet response after treatment with all eligible emergent pharmacotherapies. With 100% agreement, the working group established that pediatric patients with ITP that continue to demonstrate high disease burden and/or no platelet response despite treatment with multiple classes of disease-modifying therapies represent a challenging subset of ITP. These patients are at higher risk of ongoing disease burden and merit additional investigation as well as consideration for clinical trials or novel therapies. Future efforts to define disease burden and disease response will be completed in collaboration with the ITP International Working Group.

Published
2024
Full Text
View/download PDF

38. Mental health, pain and likelihood of opioid misuse among adults with sickle cell disease

Author

Jonassaint, Charles R., primary, Parchuri, Ektha, additional, O'Brien, Julia A., additional, Lalama, Christina M., additional, Lin, Jonathan, additional, Badawy, Sherif M., additional, Hamm, Megan E., additional, Stinson, Jennifer, additional, Lalloo, Chitra, additional, Carroll, C. Patrick, additional, Saraf, Santosh L., additional, Gordeuk, Victor R., additional, Cronin, Robert, additional, Shah, Nirmish, additional, Lanzkron, Sophie M., additional, Liles, Darla, additional, Trimnell, Cassandra, additional, Bailey, Lakiea, additional, Lawrence, Raymona H., additional, and Abebe, Kaleab Z., additional

Published
2024
Full Text
View/download PDF

42. Intensive Care Risk and Long-Term Outcomes in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Author

Zinter, Matt S, primary, Brazauskas, Ruta, additional, Strom, Joelle, additional, Chen, Stella, additional, Bo-Subait, Stephanie, additional, Sharma, Akshay, additional, Beitinjaneh, Amer, additional, Dimitrova, Dimana, additional, Guilcher, Gregory, additional, Preussler, Jaime M., additional, Myers, Kasiani C, additional, Bhatt, Neel S., additional, Ringden, Olle, additional, Hematti, Peiman, additional, Hayashi, Robert J., additional, Patel, Sagar S., additional, De Oliveira, Satiro, additional, Rotz, Seth J., additional, Badawy, Sherif M, additional, Nishihori, Taiga, additional, Buchbinder, David K, additional, Hamilton, Betty K., additional, Savani, Bipin N, additional, Schoemans, Hélène M., additional, Sorror, Mohamed Lotfy, additional, Winestone, Lena E., additional, Duncan, Christine, additional, Phelan, Rachel, additional, and Dvorak, Christopher C, additional

Published
2023
Full Text
View/download PDF

44. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases

Author

Broglie, Larisa, Friend, Brian D., Chhabra, Saurabh, Logan, Brent R., Bupp, Caitrin, Schiller, Gary, Savani, Bipin N., Stadtmauer, Edward, Abraham, Allistair A., Aljurf, Mahmoud, Badawy, Sherif M., Perez, Miguel Angel Diaz, Guinan, Eva C., Hashem, Hasan, Krem, Maxwell M., Lazarus, Hillard M., Rotz, Seth J., Wirk, Baldeep, Yared, Jean A., Pasquini, Marcelo, Thakar, Monica S., and Sorror, Mohamed L.

Published
2023
Full Text
View/download PDF

45. Health‐related quality of life with standard and curative therapies in thalassemia: A narrative literature review.

Author

Shah, Richa and Badawy, Sherif M.

Subjects
*QUALITY of life, *LITERATURE reviews, *NARRATIVE therapy, *BLOOD transfusion, *PHYSICAL mobility, *FETAL hemoglobin
Abstract

Health‐related quality of life (HRQOL) is a patient‐reported outcome that assesses the impact of a disease or illness on different domains of a patient's life. Different general and disease‐specific measures can be used to evaluate HRQOL. This article aimed to summarize the evidence for HRQOL among patients with transfusion‐dependent (TDT) and non‐transfusion‐dependent thalassemia (NTDT). We included HRQOL data related to standard therapy with blood transfusions, iron chelation, and/or luspatercept in TDT and NTDT, as well as curative therapies for TDT, including hematopoietic stem cell transplant (HSCT) and gene therapy. Patients with thalassemia had worse HRQOL scores compared to the general population, and chronic pain was seen to increase in frequency and severity over time with age. NTDT patients reported worse physical health and functioning, mental health, general health, and vitality than TDT patients. However, TDT patients reported worse pain, change in health, and social support than NTDT. Most therapies improved overall HRQOL among thalassemia patients. Deferasirox, an oral iron chelator, was associated with more HRQOL benefits compared to deferoxamine, an intravenous iron chelator. Luspatercept showed clinically meaningful improvement in physical functioning among TDT and NTDT. Furthermore, HSCT and gene therapy were associated with better physical, emotional, and mental domains scores. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., primary, Wang, Tao, additional, Chen, Karen, additional, Arora, Mukta, additional, Brazauskas, Ruta, additional, Spellman, Stephen R., additional, Kitko, Carrie, additional, MacMillan, Margaret L., additional, Pidala, Joseph A., additional, Badawy, Sherif M., additional, Bhatt, Neel, additional, Bhatt, Vijaya R., additional, DeFilipp, Zachariah, additional, Diaz, Miguel A., additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz, additional, Hashmi, Shahrukh, additional, Hematti, Peiman, additional, Hossain, Nasheed M., additional, Inamoto, Yoshihiro, additional, Lekakis, Lazaros J., additional, Sharma, Akshay, additional, Solomon, Scott, additional, Lee, Stephanie J., additional, and Couriel, Daniel R., additional

Published
2023
Full Text
View/download PDF

50. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators

Author

Pizzo, Alex, primary, Porter, Jerlym S., additional, Carroll, Yvonne, additional, Burcheri, Adam, additional, Smeltzer, Matthew P., additional, Beestrum, Molly, additional, Nwosu, Chinonyelum, additional, Badawy, Sherif M., additional, Hankins, Jane S., additional, Klesges, Lisa M., additional, and Alberts, Nicole M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results